Centiva Capital LP Buys 12,132 Shares of Novo Nordisk A/S (NYSE:NVO)

Centiva Capital LP grew its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 138.4% during the third quarter, according to the company in its most recent disclosure with the SEC. The fund owned 20,898 shares of the company’s stock after buying an additional 12,132 shares during the quarter. Centiva Capital LP’s holdings in Novo Nordisk A/S were worth $2,488,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the stock. 1620 Investment Advisors Inc. acquired a new position in shares of Novo Nordisk A/S during the second quarter worth $25,000. Strategic Investment Solutions Inc. IL acquired a new position in shares of Novo Nordisk A/S during the second quarter worth $25,000. Gilliland Jeter Wealth Management LLC lifted its holdings in shares of Novo Nordisk A/S by 200.0% during the second quarter. Gilliland Jeter Wealth Management LLC now owns 180 shares of the company’s stock worth $26,000 after purchasing an additional 120 shares during the period. Daiwa Securities Group Inc. acquired a new position in shares of Novo Nordisk A/S during the third quarter worth $28,000. Finally, Abound Wealth Management lifted its holdings in shares of Novo Nordisk A/S by 257.4% during the second quarter. Abound Wealth Management now owns 218 shares of the company’s stock worth $31,000 after purchasing an additional 157 shares during the period. Institutional investors own 11.54% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on the stock. StockNews.com upgraded shares of Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a report on Friday, November 1st. Cantor Fitzgerald restated an “overweight” rating and issued a $160.00 target price on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. Finally, BMO Capital Markets dropped their target price on shares of Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating on the stock in a report on Thursday, October 17th. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, Novo Nordisk A/S presently has an average rating of “Buy” and a consensus target price of $144.50.

Novo Nordisk A/S Price Performance

Shares of NYSE NVO opened at $108.70 on Tuesday. The firm’s 50-day moving average price is $112.81 and its 200-day moving average price is $127.92. Novo Nordisk A/S has a 1-year low of $94.73 and a 1-year high of $148.15. The firm has a market capitalization of $487.77 billion, a P/E ratio of 35.18, a P/E/G ratio of 1.38 and a beta of 0.40. The company has a current ratio of 0.94, a quick ratio of 0.75 and a debt-to-equity ratio of 0.43.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.